The WACC of Lionco Pharmaceutical Group Co Ltd (603669.SS) is 9.8%.
| Range | Selected | |
| Cost of equity | 8.80% - 11.60% | 10.20% |
| Tax rate | 3.20% - 4.80% | 4.00% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 8.5% - 11.1% | 9.8% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 6.1% | 7.1% |
| Adjusted beta | 0.99 | 1.11 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.80% | 11.60% |
| Tax rate | 3.20% | 4.80% |
| Debt/Equity ratio | 0.08 | 0.08 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 8.5% | 11.1% |
| Selected WACC | 9.8% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 603669.SS:
cost_of_equity (10.20%) = risk_free_rate (2.95%) + equity_risk_premium (6.60%) * adjusted_beta (0.99) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.